CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 344 enrolled
Drug / intervention
MRI and PET scanprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03129269
NCT03129269N/ACompleted
CompareCT.gov

Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults

University Hospital, Toulouse·interventional·Posted Apr 26, 2017·Updated May 4, 2026

In Brief

A clinical study evaluating MRI and PET scan for Frail Elderly. Completed, enrolled 344 participants across 1 site.

Detailed Summary

The current study seeks to examine the prevalence of amyloid pathology, among patients referred to the Toulouse Geriatric Frailty Clinic presenting objective memory impairment. We also aim to fully characterize the clinical progression of frail cognitively impaired patients presenting AD (Alzheimer Disease) pathology vs those who also present a cognitive impairment but do not have AD pathology.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFrail Elderly
CountriesFrance
CollaboratorsMSDAVENIR

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedApr 26, 2017
Enrollment StartJan 2, 2017
Primary CompletionJun 16, 2024
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 9.2 years ago

Interventions

MRI and PET scanprocedure

Neuroimaging with MRI and PET scan Amyloid tracer : For PET-scans, 4 MBq/kg of \[18F\]AV-45 will be injected into each subject in an intravenous bolus.